Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Nature medicine

Topics

Chemistry

Biochemistry

Medicine

Cancer Oncology

Immunology

Show all topics

DOI

10.1038/s41591-022-01754-x

License

CC-BY

Other Formats

PDF